GlassScriptPhysician profile
Amanda L Senatore
NPI 1457591653
$1,140.88
in general payments reported to CMS, 2019-2025
27 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $463 · 2023: $289 · 2024: $33.17 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $141.48 | 2022-2023 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $130.36 | 2021-2023 | Rytary |
| Corium, LLC | $97.48 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $88.39 | 2022 | |
| Genzyme Corporation | $80.95 | 2021-2022 | |
| Sanofi Pasteur INC. | $59.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $48.80 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.47 | 2022 | |
| Upsher-Smith Laboratories LLC | $44.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.61 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $33.13 | 2021 | |
| Avion Pharmaceuticals | $32.30 | 2023 | Dhivy, Methylphenidate Hydrochloride |
| Tris Pharma INC | $31.92 | 2022 | |
| Merck Sharp & Dohme LLC | $30.50 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ucb, INC. | $26.89 | 2022-2024 | Nayzilam |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.03 | 2025 | Nexplanon |
| Biogen, INC. | $21.64 | 2022 | |
| Cranial Technologies, INC | $19.53 | 2025 | Doc Band |
| Sobi, INC | $19.17 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2024 | Flumist Quadrivalent |
| Abbvie INC. | $17.85 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.10 | 2022 | |
| Neos Therapeutics, LP | $15.44 | 2022 | |
| Lilly USA, LLC | $13.88 | 2022 | |
| Aytu Biopharma, INC. | $13.34 | 2023 | Karbinal |
| Nevro Corp. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Senatore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.